Shares of Fate Therapeutics Inc (NASDAQ:FATE) have been given an average recommendation of “Buy” by the sixteen ratings firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $22.77.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Guggenheim reaffirmed a “hold” rating on shares of Burlington Stores in a research note on Thursday, May 30th. Oppenheimer assumed coverage on shares of Fate Therapeutics in a research note on Friday. They issued an “outperform” rating and a $27.00 price target on the stock. Svb Leerink assumed coverage on shares of Fate Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, Mizuho assumed coverage on shares of CytomX Therapeutics in a research note on Wednesday, June 12th. They issued a “buy” rating and a $16.00 price target on the stock.

In other Fate Therapeutics news, insider Daniel D. Shoemaker sold 12,500 shares of the stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $20.21, for a total transaction of $252,625.00. Following the transaction, the insider now directly owns 148,091 shares in the company, valued at approximately $2,992,919.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO J Scott Wolchko sold 8,541 shares of the stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $16.17, for a total transaction of $138,107.97. Following the transaction, the chief executive officer now owns 375,973 shares in the company, valued at $6,079,483.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,376 shares of company stock worth $668,402. 23.19% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of the business. Rhumbline Advisers boosted its holdings in shares of Fate Therapeutics by 1.1% in the 1st quarter. Rhumbline Advisers now owns 80,220 shares of the biopharmaceutical company’s stock valued at $1,409,000 after buying an additional 841 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Fate Therapeutics by 9.9% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,624 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 1,139 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of Fate Therapeutics by 248.5% in the 1st quarter. Meeder Asset Management Inc. now owns 2,826 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 2,015 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Fate Therapeutics by 34.8% in the 4th quarter. Jane Street Group LLC now owns 13,656 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 3,529 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Fate Therapeutics by 48.6% in the 4th quarter. Legal & General Group Plc now owns 11,376 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 3,719 shares in the last quarter. Institutional investors own 93.28% of the company’s stock.

FATE stock traded up $1.09 during trading on Monday, hitting $21.54. The company had a trading volume of 923,940 shares, compared to its average volume of 819,810. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -18.10 and a beta of 1.65. Fate Therapeutics has a 52-week low of $8.64 and a 52-week high of $22.61. The firm has a 50 day moving average of $19.49. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.40 and a quick ratio of 6.40.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.07). The company had revenue of $2.63 million during the quarter, compared to analysts’ expectations of $2.01 million. Fate Therapeutics had a negative return on equity of 54.30% and a negative net margin of 1,138.12%. The company’s quarterly revenue was up 156.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.27) EPS. As a group, analysts anticipate that Fate Therapeutics will post -1.29 earnings per share for the current year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Featured Story: Market Capitalization

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.